Is HCV genotyping cost-effective even when the prevalences of genotypes 2 and 3 are low?
Tahan V, Ozaras R, Karaca C, Uraz S, Eren F, Danalioglu A, Avsar E, Turkoglu S, Midilli K, Tabak F, Ozturk R, Mert A, Senturk H, Tozun N.
Tahan V, et al. Among authors: senturk h.
Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1425-8.
Hepatogastroenterology. 2009.
PMID: 19950804